Picture of ADC Therapeutics SA logo

ADCT — ADC Therapeutics SA Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m-15.4%
3m-34.03%
6m-28.38%
1yr-57.49%
Volume Change (%)
10d/3m+7.25%
Price vs... (%)
52w High-50.87%
50d MA-23.37%
200d MA-29.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-47.86%
Return on Equity-89.31%
Operating Margin-1638.02%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of ADC Therapeutics SA EPS forecast chart

Profile Summary

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
June 6th, 2011
Public Since
October 3rd, 2019
No. of Shareholders
74
No. of Employees
208
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
76,721,697

ADCT Share Price Performance

Latest News for ADCT

Upcoming Events for ADCT

Q4 2021 ADC Therapeutics SA Earnings Release

Q1 2022 ADC Therapeutics SA Earnings Release

ADC Therapeutics SA Annual Shareholders Meeting

Similar to ADCT

Ambrx Biopharma

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

Picture of Arcus Biosciences logo

Arcus Biosciences

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email